Scope of Nuclear Medicine in the management of thyroid carcinoma:
Among thyroid carcinomas, differentiated thyroid carcinoma (DTC) can be treated with radioactive iodine (RAI) 131 I due to iodine uptake property of malignant follicular cells. Besides discussions to prepare this guideline many published guidelines, relevant articles published in authentic international journals and experiences of NINMAS were considered.
Management of DTC
• Total thyroidectomy is the mainstay of treatment. • RAI ablation should be completed within 4-6 weeks of thyroidectomy
Goal of RAI ablation
• As adjuvant therapy- 
Prerequisites of RAI ablation
For successful ablation TSH should be >30 mIU/L after total thyroidectomy (TT) or near total thyroidectomy (NTT).
• • In case of large remnant tissue-RAIU >5-10% with large remnant tissue in thyroid bed on 99m Tc scan and TSH not raised up to required level, further surgery is recommended.
• If further surgery is refused due to adhesionrepeated low activity therapies with 30-50 mCi of 131 I at 3-4 months interval should be considered.
• In case of cervical lymphadenopathy-neck dissection is mandatory.
• Remnant ablation can be done following rhTSH (Thyrogen) stimulation keeping on LThyroxin.
• Following things should be discussed with patients and relatives:
-Rationale, procedure, and side-effects of RAI therapy, -Isolation and radioprotection during stay in the hospital & after discharge and -Mode of future follow-up.
• Written informed consent is to be taken before administration of RAI.
• Patient should be in low iodine diet (<50 µgm/d of dietary iodine) for 2 weeks before and 1-2 days after 131 I therapy (Annexure 7).
• In cases of radiographic contrast injection (e.g. contrast CT) 131 I therapy should be postponed for 2-3 months.
• Pregnancy and lactation should be excluded in case of female patients.
• In case of lactating mother-RAI therapy should be given 6-8 weeks after cessation of breast-feeding.
Procedure
• Patients should be hospitalized for 131 I therapy.
• 30-100 mCi is administered for remnant ablation.
• Higher activities (100-200 mCi) are selected for lymph node and distant metastases.
• In pediatric patients activities of 131 I should be adjusted according to body weight or surface area.
• To avoid vomiting following RAI administration -Give anti-emetics before mid-day meal (as RAI usually administered in afternoon) and -No food should be allowed for at least 2 hours before and 1 hour after RAI administration • Supportive medicines like anxiolytic, antiulcerent, NSAID should be advised.
• Vitamin C, lemon candies and other sialagogues should be started after 24 hours.
• Start L-thyroxine (LT4) on 2 nd or 3 rd posttherapy day (PTD) in incremental dose.
• Calcium supplementation with vitamin D is given where necessary.
• Calcitriol should be given in selective cases.
• Purgatives are given on the 2 nd or 3 rd posttherapy day.
• Patients are advised to drink plenty of liquid from 1 st post-therapy day and empty bladder frequently.
Isolation and radioprotection
• No visitor should be allowed during first 24 hours.
• No contact with children and pregnant women for 10-15 days.
• Adults may be allowed for short period of time keeping sufficient distance (>1 meter) (Annexure 8).
• Duration of isolation can be calculated using age and kidney factor (Annexure 9).
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Release from isolation
• Patients can be released from isolation when survey meter count is 20-25 µSv/h at 1 meter distance.
• Tumor uptake is confirmed by post-therapy whole body scan (RxWBS) 2-10 days after therapeutic dose.
• In NINMAS, RxWBS is usually done on 5 th PTD and patients are released from isolation with survey meter count is <10 µSv/h at 1 m distance.
Instructions during discharge
• To reduce external exposure to others:
-Limit time spend in public place. -Avoid mouth to mouth contact. -Do not share item that comes in contact with mouth or saliva (eating utensils, water bottles). -Use separate towels and washcloths.
-Wash utensils and plates separately. -Wash hands thoroughly after going to toilet. -Do not cook and feed children.
• Avoid pregnancy for one year and fathering a child for 6 months following RAI therapy
Care about contaminated items (please see Annexure 10).
Pathological and clinical staging after RAI ablation
• Benefit of staging:
-Staging at this stage allows risk stratification of individual patient which in turn will dictate the frequency and type of follow-up. -Staging of DTC is based on the pathological assessment with addition of information derived from the RxWBS.
• Low risk patients:
-No tumor invasion in loco-regional tissue or structure, -No vascular invasion, -All microscopic tumor has been resected, -Tumor does not have aggressive histology (e.g. tall cell, columnar cell, insular), and -No uptake outside thyroid bed on RxWBS.
• Intermediate risk patients:
-Microscopic invasion of tumor into the peri-thyroidal soft tissues at the initial surgery, -Tumor with aggressive histology, -Vascular invasion, -Cervical lymph node metastases, and -131 I uptake outside the thyroid bed on the RxWBS.
• High-risk patients:
-Macroscopic tumor invasion, -Incomplete tumor resection, -Distant metastases, and -Thyroglobulinemia irrespective of findings on RxWBS.
Thyrotropin-suppressive therapy
• Rationale & recommendation: -To correct hypothyroidism and -To inhibit TSH dependent growth of residual cancer cells by suppressing TSH.
• L-thyroxine (LT4) is the drug of choice 
Follow-up after initial therapy
• Objectives of follow up:
-To ensure that the patients receive lowest effective dose of LT4 i.e. one that provides required TSH suppression -To discover at the earliest possible time persistent or recurrent disease • At this stage, TSH ≤0.1 mIU/L, normal FT3 and normal or high FT4 level denote an appropriate dose of LT4.
• Patient is considered as no evidence of disease:
-complete tumor resection according to the surgeon's report, -no uptake outside the thyroid bed on RxWBS, -undetectable Tg levels (< 1 ng/ml during LT4 treatment) and -no abnormality on neck US.
• In case of persistent disease further therapy is delayed for 6-12 months.
Second follow-up
• The 6-month follow-up (on LT4)
For patient without evidence of disease at 3-month, the 6 -month follow-up consists of 
Subsequent follow-up
• With undetectable Tg, negative DxWBS and normal US findings at 6 to 12-month follow-up, the risk of recurrence is < 0.5%.
• Reduced dose of LT4 to allow TSH concentration of 0.1 -0.5 mIU/L.
• Follow up patients twice yearly with TSH, Tg, anti Tg antibody and US of neck keeping patient on LT4.
• Further DxWBS should be done whenever necessary.
Further RAI therapy
• Detectable stimulated Tg should be followed up and a rising Tg should be considered as persistent or recurrent disease and should be treated with high activities of 131 I.
• Positive DxWBS needs further RAI therapy with higher activities.
Management of loco-regional metastases
• Surgery is favored for loco-regional recurrence (cervical LNs and soft tissue tumor in the neck) when distant metastasis is absent. Surgery should be followed by 131 I therapy.
• For aerodigestive invasion, surgical resection followed by RAI and/or external beam radiotherapy (EBRT) is recommended.
• If surgery is not possible, EBRT followed by RAI is recommended.
• Ethanol injection is considered in cases of enlarged lymph nodes (<2 cm) where operative treatment is refused and multiple RAI therapy is failed.
Management of pulmonary metastases
• Pulmonary micro-metastases-RAI therapy is recommended and it should be repeated every 6-12 months as long as disease concentrates RAI and respond clinically.
• Empiric dose 100-200 mCi.
• Macronodular metastases may also be treated with RAI if it is iodine avid and should be repeated when objective benefit is demonstrated (i.e. decrease in the size of lesion, decreasing Tg).
• Glucocorticoids should be given in case of known pulmonary metastases along with 131 I to prevent radiation induced pulmonary fibrosis.
• Non-RAI avid pulmonary disease--No benefit with RAI.
-Not detected by DxWBS.
-May be detected by 18 FDG-PET scan. -May be benefited with chemotherapyDoxorubicin and cisplatine.
Management of bone metastases
• Complete surgical resection of isolated metastasis is recommended.
• Prognosis can be improved if 131 I is given at an early stage (when bone metastases are detected in RxWBS but radiograph is negative).
• DxWBS should be done at 6 th month follow-up and therapy is to be repeated if positive.
• In cases of metastasis detected in first RxWBS-150 mCi of 131 I should be given at 6 months interval until RxWBS is negative.
• At advanced stage when radiograph shows metastases-give 150 mCi of 131 I at 4-6 months interval until RxWBS is negative.
• 131 I should not be interrupted as long as metastases are 131 I avid, whatever the cumulative activity reached.
• Stable disease particularly when longstanding, a strategy of 'watchful waiting' can be employed.
• EBRT and glucocorticoids should be given prior to RAI therapy to minimize radiation related tumor expansion and pain exacerbation.
• Zolendronate infusions should be considered to prevent fracture.
• Ibandronate may be given in place of Zolendronate.
• Painful lesions that cannot be resected can be treated by intra-arterial embolization, radiofrequency ablation etc.
Management of brain metastases
• Complete surgical resection is first line of treatment.
• Where surgery is not possible consider EBRT.
• RAI therapy should be considered for iodine avid lesions.
• Glucocorticoid therapy is strongly recommended prior to EBRT and during RAI therapy to minimize subsequent inflammatory effects.
Tg positive-DxWBS negative patients
• 201 Tl or 99m Tc scan may be done to detect metastases or • Empiric RAI therapy (100-200 mCi) may be given.
• If RxWBS is negative, no further RAI therapy should be administered.
• 18 FDG-PET scan may be done to locate metastases.
• RAI negative-PET positive patients have poor survival. • EBRT, chemotherapy may be considered at this stage. Hypocalcaemia
• Hypocalcaemia following total thyroidectomy is quite common.
• It is due to either devascularization or accidental removal of parathyroid glands.
• It is a grave condition which needs early detection and meticulous management.
• High doses of calcium with vitamin D should be administered.
• Alfacalcidol or Calcitriol have to be added in some cases.
• In cases of severe hypocalcaemia injectable calcium is needed (should be managed by endocrinologists).
• Patients taking high doses of calcium and calcitriol following surgery should be checked for serum calcium & PTH level and calcium supplementation should be considered accordingly.
• When calcium is administered patient should be monitored carefully:
-Serum calcium should be measured at 2/3 months interval and -US of kidney and serum creatinine should be checked yearly.
Annexure 1. Thyroid carcinoma
Types of thyroid carcinoma:
A. Epithelial cell origin • Improves effectiveness for 131 I ablation.
• Lowers dose needed for 131 I ablation.
• Allows follow up with thyroglobulin (Tg) levels.
• Decreases recurrence in all groups.
• Improved survival in high risk patients.
• Decreased risk of pulmonary metastases.
Annexure 3. Thyroidectomy
Total thyroidectomy-removal of all grossly visible thyroid tissue-both lobes, isthmus and pyramidal lobe.
Near total thyroidectomy-removal of all grossly visible thyroid tissue, leaving only a small amount (<1g) of tissue adjacent to recurrent laryngeal nerve near the ligament of Berry.
(TT or NTT alone is appropriate for small (T1 or T2), noninvasive, clinically node negative PTCs and most FTCs.)
Subtotal thyroidectomy-leaving >1g of tissue with the posterior capsule on the uninvolved side.
Hemithyroidectomy-complete removal of one thyroid lobe (involved lobe) including the isthmus. • Isotope of iodine.
• Reactor produced.
• Emits high energy gamma (364 keV).
• Decays by emitting beta particles.
• Main gamma emission is 364 keV (82%) and main beta emission is 606 keV (90%).
• Physical half life is 8.04 days, biological half life is 80 days in normal thyroid compartment and 12 days in extrathyroidal compartment and effective half life is 7.3 days in thyroid compartment and 8 hours in extrathyroid compartment.
• Beta particles penetrate 0.6 -2.0 mm.
• Bio-distributiono taken up by follicular cells of thyroid gland, salivary glands, nasal mucosa, lacrimal glands, stomach, o Excretion via intestine and urinary tract including bladder.
Annexure 7. Low-iodine diets
Avoid followings:
• So, a young person with normal kidney function (0.4) having had 150 mCi will be in phase one for: 0.4 x 150= 60 hours or 2 ½ days Similarly, an older person (60+) with impaired kidney function (1.6) having had 150 mCi will be in phase one for: 1.6 x 150= 240 hours or 10 days Phase one starts immediately after treatment dose.
Phase one ends remaining radioactivity is somewhere around 5 mCi level.
Phase two
Minimal precaution, mainly for body fluids How long is phase two Formula: 5days x age/ kidney factor= days in phase two Eg. Young person with normal kidney: 5 x 0.4 = 2 days Older person with impaired kidney: 5 x 1.6 = 8 days Patient should be § Careful about urine, saliva, avoid food tasting while cooking, kissing, can sleep next to an adult but avoid sleeping with children, babies and pregnant women. § Transition from phase one to phase two is slow in cases of significant uptake due to extensive remnant thyroid tissue or metastases. In these cases precautions should be taken for distance-avoid sitting, staying or sleeping for another few days. § In cases of low dose for large residual tissue patient should be isolated for longer time. High level:
• In contact with saliva & urine especially fabric or wipes
• Carefully clean with damp cloth, wash, either hand or washing machine.
• If washing is not practicable put out of way for 6 to 12 weeks.
Medium level:
• Items that have been handled a lot, sneezed or coughed upon
• Decontaminate with damp wipe, wash or put in isolation for 1 month
Low level:
• Items in contact with skin
• Quick wipe over
• To avoid contamination with touch rinse hands with water before touching door handles, key boards, remotes, cell phones etc Documents and articles consulted:
